{
    "2020-06-03": [
        [
            {
                "time": "2023-10-05",
                "original_text": "Pliant Therapeutics Up 33% on IPO Pricing",
                "features": {
                    "keywords": [
                        "Pliant Therapeutics",
                        "IPO Pricing",
                        "Up 33%"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "Novartis' sBLA for Ofatumumab Gets Extended Review From FDA",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Ofatumumab",
                        "Extended Review",
                        "FDA"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "The Daily Biotech Pulse: Regulatory Delay For Novartis Multiple Sclerosis Drug, FSD Gets Nod For COVID-19 Study",
                "features": {
                    "keywords": [
                        "Regulatory Delay",
                        "Novartis",
                        "Multiple Sclerosis Drug",
                        "FSD",
                        "COVID-19 Study"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotech",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}